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In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously
affected individuals is of utmost importance. We recap here evidence that supports the use of human recombinant
erythropoietin (EPO) for ameliorating course and outcome of seriously ill COVID-19 patients. This brief expert review
grounds on available subject-relevant literature searched until May 14, 2020, including Medline, Google Scholar, and
preprint servers. We delineate in brief sections, each introduced by a summary of respective COVID-19 references,
how EPO may target a number of the gravest sequelae of these patients. EPO is expected to: (1) improve respiration at
several levels including lung, brainstem, spinal cord and respiratory muscles; (2) counteract overshooting inflammation
caused by cytokine storm/ inflammasome; (3) act neuroprotective and neuroregenerative in brain and peripheral
nervous system. Based on this accumulating experimental and clinical evidence, we finally provide the research design
for a double-blind placebo-controlled randomized clinical trial including severely affected patients, which is planned to
start shortly.
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The COVID-19 (coronavirus disease 2019, caused by severe
acute respiratory syndrome coronavirus 2, SARS-CoV-2) pan-
demic has reached yet unknown dimensions and is over-
whelming societies, politics, medical systems and, in
particular, intensive care units. The development of vaccines
is ongoing but it still requires many months to years for them
to be broadly accessible. Repurposed antiviral or immuno-
modulatory drugs and antisera are being evaluated in numer-
ous, rapidly started clinical trials but thus far, despite perhaps
some mild positive signals and even one speedy temporary
approval by FDA and EMA (https://www.nih.gov/news-
events/news-releases/nih-clinical-trial-shows-remdesivir-accel-
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has hitherto evolved. Neutralizing monoclonal antibodies
against proinflammatory cytokines and their respective recep-
tors or complement inhibitors are considered as well, but all
await clinical proof-of-concept studies (Bauchner and Fonta-
narosa 2020; Cao 2020; Del Rio and Malani 2020; Grein et al.
2020; Lythgoe and Middleton 2020; Mehta et al. 2020a; San-
ders et al. 2020). First negative trials are already reported
(Casadevall et al. 2020; Li et al. 2020a; Magagnoli et al. 2020).
A substantial number of affected individuals suffer a
severe disease course, with some predominance in older
individuals, but serious and fatal outcomes also increas-
ingly observed in children and young adults. The grave
cases show pneumonia with severe hypoxemia, requiring
oxygen supply and mechanical ventilation (Li et al.
2020b; Liu et al. 2020; Mao et al. 2020; Nath 2020; Wu
and McGoogan 2020; Yang et al. 2020) not infrequently
combined with overshooting inflammatory reactions and
a so-called ‘cytokine storm’ (Cao 2020; Allen et al. 2009;le is licensed under a Creative Commons Attribution 4.0 International License,
ution and reproduction in any medium or format, as long as you give
the source, provide a link to the Creative Commons licence, and indicate if
d party material in this article are included in the article's Creative Commons
line to the material. If material is not included in the article's Creative Commons
d by statutory regulation or exceeds the permitted use, you will need to obtain
. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
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Wang et al. 2020a; Wen et al. 2020). More recently, an
appreciable number of individuals with neurological
complications has been identified, in particular among
the severely affected subjects (Li et al. 2020b; Mao et al.
2020; Nath 2020; Avula et al. 2020; Desforges et al. 2019;
Dube et al. 2018; Gandhi et al. 2020; Gu and Korteweg
2007; Helms et al. 2020; Moriguchi et al. 2020; Oxley
et al. 2020; Toscano et al. 2020; Troyer et al. 2020). In
the present therapeutic situation, which is essentially
based on comprehensive general intensive care manage-
ment, any additional measure to improve course and
outcome of seriously afflicted individuals is of consider-
able importance. This review addresses the need and po-
tential of symptom-targeting therapeutic measures.
Introducing the candidate: recombinant human
erythropoietin (EPO) – not only relevant for
anemia treatment
Erythropoietin is a hypoxia-inducible growth factor, named
after its original discovery in hematopoiesis (Jelkmann
1992; Krantz 1991). Over the last 30 years, it became more
and more clear that EPO is expressed in many organs and
tissues of the body, where it exerts multiple functions in
the sense of a pleiotropic tissue-protective cytokine. EPO
has not only successfully been used to treat or prevent
anemia (the approved indication) but also for various other
conditions, ranging from brain to different other organ dis-
eases, in both human trials and numerous animal studies.
Overall, in critically ill patients, EPO was safe and probably
efficient, as summarized in recent meta-analyses (Litton
et al. 2019; Mesgarpour et al. 2017).
Extension of EPO treatment to conditions other than
anemia has not been appropriately supported by indus-
try so far, partly due to expired patents, multiple biosi-
milar producers, fear of off-label use and of emerging
additional side effects (Sargin et al. 2010). Therefore, its
beneficial properties for treating e.g. brain disease could
not be sufficiently demonstrated yet by large clinical tri-
als needed for official approval of new indications. In the
present COVID-19 pandemic, we suggest short-term
supportive EPO treatment of severely affected patients,
which we expect to improve disease course and out-
come. Although case reports always call for extreme
caution, two recently published/submitted case studies
on EPO in seriously ill COVID-19 patients are encour-
aging for the present concept (Hadadi et al. 2020;
Wincewicz et al. 2020, in review). In addition, potential
supportive evidence is provided by the observation that
hemodialysis patients with COVID-19 are likely to ex-
perience mild disease that does not develop into full-
blown pneumonia. While the authors interpret this find-
ing as possibly due to reduced function of the immune
system and decreased cytokine storm in this patientgroup (Perico et al. 2020), we are rather inclined to see
it related to their continuous EPO treatment.
Three major levels of expected beneficial EPO
action on respiratory function in severely affected
COVID-19 patients
Severe acute respiratory syndrome of COVID-19 pa-
tients involves pulmonary and systemic inflammation,
leading to multi-organ dysfunction in patients at high
risk. Acute respiratory distress syndrome, sepsis, and
acute cardiac decompensation are the most common
critical complications during exacerbation. Approxi-
mately 15–33% of COVID-19 patients have severe
course requiring intensive care, of whom up to > 30%
need mechanical ventilation (Cao 2020; Del Rio and
Malani 2020; Wu and McGoogan 2020; Goyal et al.
2020; Wang et al. 2020b). Chest radiographs are charac-
terized by bilateral patchy infiltrates and chest comput-
erized tomography scans demonstrate ground glass
infiltrates. Histopathological findings in the lung include
hyaline membrane formation, interstitial mononuclear
inflammatory infiltrates, and multinucleated giant cells,
findings similar to those in SARS or MERS coronavirus
infections (Del Rio and Malani 2020; Munster et al.
2020). Brain invasion of SARS-CoV-2 may partially be
responsible for the acute breathing failure of patients
with COVID-19, with respiratory brainstem centers
playing a prominent role. Associated neuropathy and
myositis likely encompass phrenic nerve and respiratory
muscles (Li et al. 2020b; Mao et al. 2020; Nath 2020;
Lucchese and Floel 2020; Wu et al. 2020).
We propose that EPO will act on all three major
levels of respiratory function in severely affected
COVID-19 patients (Fig. 1). Beneficial effects of EPO
on the nervous system that could contribute to im-
proved respiration include brainstem centers and
phrenic nerve. For instance, EPO in the locus coeru-
leus attenuates the ventilatory response to CO2 in
rats, i.e. it tunes the hypercapnia-induced hyperpnoea
(Silva et al. 2017). EPO-mediated regulation of the
central respiratory command involves MEK1/2 and
PI3K (Caravagna and Soliz 2015). These pathways are
also critical for phrenic motor facilitation induced by
cervical spinal EPO, indicating that it elicits spinal
plasticity in respiratory motor control under condi-
tions of prolonged or recurrent low oxygen (Dale
et al. 2012).
Several reports exist demonstrating beneficial EPO ef-
fects on acute lung injury and the acute respiratory dis-
tress syndrome (ARDS) in various different animal
models (reviewed in (Kakavas et al. 2011)). EPO appears
to exert its pleiotropic actions in the lung by protecting
the integrity of the pulmonary epithelial and endothelial
cells as well as by attenuating the associated pulmonary
Fig. 1 Beneficial pleiotropic EPO effects on respiratory function target
several levels, comprising brainstem and central respiratory command,
lung, including protection of overall tissue homeostasis, as well as phrenic
motor facilitation and spinal plasticity in respiratory motor control
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oration of pulmonary oxygenation function (Kakavas
et al. 2011; Zhu et al. 2019). This is achieved via modu-
lating multiple levels of early signaling pathways in-
volved in apoptosis, inflammation and peroxidation,
potentially restoring overall homeostasis (Kakavas et al.
2011; Anagnostou et al. 1990; MacRedmond et al. 2009).
Furthermore, EPO appears to confer vascular protection
by promoting angiogenesis (Kakavas et al. 2011).
Encouragingly, animal models of acute lung injury, con-
sistently revealing beneficial EPO effects, comprise mul-
tiple etiologies. They include injury provoked by
hyperoxia (Ozer et al. 2005), acute necrotizing pancrea-
titis (Tascilar et al. 2007), ischemia/reperfusion (Wu
et al. 2009), sepsis induced by cecal ligation (Aoshiba
et al. 2009) or by lipopolysaccharide (Shang et al. 2009),
zymosan-induced non-septic shock (Cuzzocrea et al.
2006), tracheobronchial and pulmonary epithelial dam-
age following brain trauma (Yildirim et al. 2005) and
scald-burn inflammation (Rocha et al. 2015).
Data on EPO effects in human respiration are scarce.
In a case of severe ARDS, lung function upon EPO im-
proved and extracorporeal membrane oxygenation
(ECMO) support could be reduced (Jungebluth et al.
2015). Intravenous EPO in volunteers exposed to mild
hypoxia (10% O2 for 15 min) modulated the hypoxic
ventilatory response. This effect appears to prevail via
carotid body response, i.e. peripheral chemosensitivity,
in humans as likewise seen before in mice (Soliz et al.
2009). Only marginally related, acute mountain sickness,
characterized by headache, gastrointestinal symptoms,
weakness, dizziness or lightheadedness, and difficulty
sleeping in an unacclimatized person who recently ar-
rived at an altitude above 2500 m, was prevented by
prophylactic EPO injections (Heo et al. 2014). Efficacy ofEPO versus placebo in critically ill patients, including
those with lung disease admitted to intensive care,
yielded reduction in allogeneic red blood cell transfu-
sion. This trial did not evaluate effects on respiration,
however, mortality and serious adverse events were not
different between treatments, reassuring safety in pul-
monary disease subjects (Silver et al. 2006).
EPO to counteract inflammation and ‘cytokine
storm’ in COVID-19
Pneumonia, lymphopenia, lymphocyte exhaustion
markers and cytokine storm characterize severe COVID-
19. CRP and D-dimer are abnormally high. Substantially
elevated serum levels of proinflammatory cytokines, in-
cluding IL-6, IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF
and others, contribute to shock and multi-organ damage
as well as to extremely diminished numbers of CD4+ T
cells, CD8+ T cells, B cells, natural killer cells, mono-
cytes, eosinophils and basophils (Cao 2020; Liao et al.
2020; Wen et al. 2020). In addition, SARS-CoV-2 infec-
tion of T cells could potentially induce T cell apoptosis
(Wang et al. 2020a).
The nucleotide-binding domain and leucine-rich
repeat-containing (NLR) family of pattern-recognition
molecules mediate host immunity to various viral patho-
gens. Experiments utilizing analogs of dsRNA (poly-I:C)
and ssRNA (ssRNA40) demonstrated that an NLRP3-
mediated response could be activated by ‘virus mimetic’
RNA species (Allen et al. 2009). Whereas the NLRP3
inflammasome is an essential component in host defense
against infection through sensing of viral RNA (Ivanov
et al. 2020), its overshooting activity can be highly de-
structive. An excessive inflammatory response results in
the progression of ARDS, with the NLRP3 inflamma-
some as key player.
Interestingly, EPO can effectively attenuate lung injury
in mice by suppressing the NLRP3 inflammasome, which
is dependent upon activation of EPOR/JAK2/STAT3 sig-
naling and inhibition of the NF-kB pathway (Cao et al.
2020). This protective, balancing EPO mechanism might
also be exploited for COVID-19 invasion into the brain,
since in microglia, the NLRP3 inflammasome becomes
(over) activated, too, when these cells sense virus. Subse-
quent caspase1 cleavage then markedly contributes to dis-
ease development and progression (Heneka et al. 2018).
EPO is probably in many instances of COVID-19 asso-
ciated cytokine storm a better option than the ultima ra-
tio immunosuppression (Mehta et al. 2020b), which may
weaken, complicate or even endanger proper host
defense. EPO suppresses proinflammatory cytokines,
protects cells from apoptosis and promotes wound heal-
ing. EPO receptors (EPOR) are expressed on a variety of
immune cells, enabling EPO to directly modulate their
activation, differentiation and function (Peng et al. 2020;
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burst activates macrophage EPO signaling to promote
the resolution of acute inflammation (Luo et al. 2016).
Both immunomodulation and anti-inflammation medi-
ated by EPO promise another set of beneficial effects in
severe COVID-19. In fact, combined use of EPO as anti-
inflammatory as well as immunomodulatory treatment
and antiviral drugs may even be more effective than
using either one alone. Additionally, known side effects
of antiviral drugs observed in SARS include anemia,
which may improve upon EPO (e.g. (Fujii et al. 2004)).
EPO: the case for neuroprotection in COVID-19
Neurologic manifestations of COVID-19 patients are in-
creasingly reported, resemble symptoms/syndromes ob-
served in SARS, occur most pronounced in severe cases,
and range from headache, dizziness, impaired taste,
smell or vision, ataxia, pain, nausea, delirium, seizures,
meningoencephalitis, and impaired consciousness, to
Guillain Barré syndrome, peripheral nervous system and
skeletal muscle dysfunction/myositis (Mao et al. 2020;
Nath 2020; Helms et al. 2020; Toscano et al. 2020; Wu
et al. 2020; Baig 2020; Steardo et al. 2020). Very recently,
a number of patients, many younger than 50 years, pre-
sented with radiographically confirmed acute stroke and
PCR-confirmed SARS-CoV-2 infection, which empha-
sizes once more that neurological presentations of
COVID-19 can be manifold (Avula et al. 2020; Oxley
et al. 2020). Past viral pandemic-related outcomes also
include neuropsychiatric symptoms, such as encephalop-
athy, mood changes, psychosis, or demyelinating pro-
cesses, which accompanied acute viral infection or
followed infection by weeks, months, or longer in recov-
ered patients (Desforges et al. 2019; Moriguchi et al.
2020; Troyer et al. 2020; Moldofsky and Patcai 2011).
Presence and persistence of human coronaviruses in hu-
man brain have been proposed to cause long-term se-
quelae (Troyer et al. 2020). All these observations are
less surprising considering the viral spread via axons and
neuron-to-neuron propagation, as known from SARS
and other coronavirus infections in mammals (Dube
et al. 2018; Gu and Korteweg 2007; Gu et al. 2005; Li
et al. 2013; Netland et al. 2008). Coronaviruses may in-
vade the CNS, disseminate, and participate in the induc-
tion of neurological diseases. Animal models revealed
the route of neuropropagation from nasal cavity to olfac-
tory bulb, piriform cortex and brainstem (Dube et al.
2018; Netland et al. 2008). Neurodestructive processes,
including immune-mediated damage or exacerbated
autoimmunity (Cao 2020; Toscano et al. 2020; Troyer
et al. 2020; Lucchese and Floel 2020; Moldofsky and
Patcai 2011; Lo et al. 2006; Zhang et al. 2020) may
thereby well be initiated and contribute to neurodegen-
erative diseases like Morbus Alzheimer and otherdementias as late consequences. Therefore, neuroprotec-
tive strategies should be initiated in severely affected
COVID-19 patients without any delay.
EPO appears as a well-suited candidate to provide the
required lasting and comprehensive neuroprotection. In
the mammalian brain, EPO and EPO receptor (EPOR)
expression is upregulated upon pathological conditions,
e.g. brain injury of different etiologies, where it exerts
anti-apoptotic, neuroprotective and neuroregenerative
effects, independent of hematopoiesis (Brines and
Cerami 2005; Digicaylioglu et al. 1995; Marti et al. 1996;
Shingo et al. 2001). Taking an unusual reverse approach
(human trials first), we reported that EPO treatment has
potent neuroprotective and procognitive properties in
patient groups as different as ischemic stroke, chronic
schizophrenia, chronic progressive multiple sclerosis,
treatment-resistant major depression and bipolar disease
(Ehrenreich et al. 2007a; Ehrenreich et al. 2007b;
Miskowiak et al. 2014a; Miskowiak et al. 2014b). In
schizophrenia and affective disorders, we even detected
in independent trials reduction of grey matter loss upon
EPO (Miskowiak et al. 2015; Wustenberg et al. 2011).
Animal studies performed over more than two decades
confirmed these beneficial effects in a multitude of dif-
ferent disease models and started to provide mechanistic
insight into the (patho) physiological role of the en-
dogenous brain EPO system which includes strong ef-
fects on neurodifferentiation and neuroplasticity (Sargin
et al. 2010; Sakanaka et al. 1998; Wakhloo et al. 2020).
To achieve sufficiently high neuroprotective concentra-
tions in the brain - independent of an intact or during
COVID-19 potentially compromised blood-brain-barrier
- high-dose intravenous EPO must be recommended as
successfully used in our clinical studies on brain diseases
mentioned above. To avert possible hematopoietic side
effects of EPO, routine laboratory screening and - if indi-
cated - preventive measures accompany each EPO appli-
cation (for detailed description see (Bartels et al. 2008)).
Taken together, EPO might have the potential to im-
prove outcome of COVID-19 patients regarding acute as
well as chronic-progressive downstream sequelae of the
central and peripheral nervous system.
EPO indications outside the hematopoietic system:
difficult ever since - but worthwhile pursuing
After > 20 years of own experience in translational work
on the brain EPO system, including many clinical trials,
we feel that the following points need to be addressed in
the context of this review and before presenting our de-
sign of a proof-of-concept trial on EPO treatment in
COVID-19 below.
Work on EPO indications outside the hematopoietic
system has been challenging ever since, not only because
of difficulties obtaining funding as above mentioned
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of pharmaceutical companies and subsequently regula-
tory bodies drawing premature conclusions based on too
superficially or not at all analyzed data. This did not only
damage further work on EPO in stroke (Ehrenreich et al.
2009), but also influenced other EPO trials negatively
(e.g. (Grasso et al. 2016)). To add to the problematic
situation, studies with suboptimal trial/endpoint design
despite preexisting knowledge clearly did not benefit the
‘overall reputation of EPO’ (Ehrenreich et al. 2020). Sci-
entifically unfounded conclusions triggered > 10 years
ago an avalanche of destruction regarding the German
EPO stroke multicenter trial where inclusion/treatment
violations of stroke patients in most of the recruiting
centers (totally independent of the study medication) ex-
plained the outcome rather than EPO itself (Ehrenreich
et al. 2009). In fact, careful subpopulation analysis of all
deceased patients revealed that several relevant baseline
characteristics (i.e. data obtained before administration
of any study medication) were significantly different be-
tween groups, always in disadvantage of the EPO group.
For instance, upon inclusion (before study drug applica-
tion), intent-to-treat non-rtPA patients receiving EPO,
who died, suffered from much severer strokes as com-
pared to placebo patients (NIHSS day 1: 20.4 ± 5.4 versus
13.3 ± 4.9; p = 0.003). This highly significant prediction
of a worse outcome explains the twofold higher very
early death rate in the EPO group (for more information,
visit http://www.epo-study.de/index_eng.html).
In addition, the multicenter EPO stroke trial had to
run over several years due to lack of funding in between,
and exactly during this time, rtPA treatment in Germany
rose dramatically (including numerous violations of rtPA
indications in all but one of the trial centers). This cer-
tainly added much to the overall negative trial outcome.
Importantly, we note that regarding non-rtPA patients,
the originally reported benefit of EPO (Ehrenreich et al.
2002) was fully reproduced in this multicenter trial
(Ehrenreich et al. 2009). In fact, not only the outcome of
this non-rtPA subgroup (Ehrenreich et al. 2009) and the
first EPO stroke trial (Ehrenreich et al. 2002) were
promising. Also the retrospective analysis of patients
only from Hannover, the most efficiently recruiting cen-
ter of the multicenter EPO stroke trial, with essentially
no violations of inclusion criteria and lege artis rtPA
treatment, made the beneficial effect of EPO in stroke
(independent of rtPA) once more obvious (Worthmann
et al. 2013).
Longer treatment duration - over many weeks - may
ultimately enhance the benefit of EPO for neuroprotec-
tion and neuroregeneration also after stroke. Clinical
studies on EPO in chronic brain diseases (schizophrenia,
multiple sclerosis, major depression and bipolar dis-
order) with extended treatment using high-dose EPOover many weeks showed consistently advantageous ef-
fects on cognition, motor function, and even reduction
of brain matter loss (Ehrenreich et al. 2007a; Ehrenreich
et al. 2007b; Miskowiak et al. 2014a; Miskowiak et al.
2014b; Miskowiak et al. 2015; Wustenberg et al. 2011).
All these findings were in absence of any noticeable side
effects. Therefore, in light of more and more reports on
and predictions of long-term consequences of COVID-
19 in the sense of a virus-induced post-infection neuro-
degenerative course (delineated in the previous section),
not only the potential for acute treatment of SARS-CoV-
2 by EPO, but also the substantial chance for chronic
treatment might be worthwhile considering.
Of course, in all clinical EPO studies, the quality of pa-
tient care including alert follow-up of individual patients
at all times is mandatory (Bartels et al. 2008; Siren et al.
2009). EPO is a potent growth factor, not a miracle drug,
and it is no causal treatment or cure of brain diseases
but it may improve their outcome.Design of a proof-of-concept trial on EPO
treatment in COVID-19
Based on the experimental and clinical studies on EPO
summarized in the above sections, we hypothesize that
EPO treatment has positive effects on clinical course
and outcome of critically ill COVID-19 patients. A
proof-of-concept study of EPO in COVID-19 is there-
fore in preparation (Fig. 2).
In this planned double-blind, placebo-controlled, ran-
domized proof-of-concept (phase IIb) trial with safety/
futility assessment following enrollment of 20 and 40 pa-
tients, respectively, the proportion of patients with clin-
ical improvement from WHO R&D Blueprint ordinal
scale grade 6 (hospitalized, on invasive mechanical venti-
lation or ECMO) to grade 5 (hospitalized, on non-
invasive ventilation or high flow oxygen devices) on day
14 will be the primary outcome. EPO treatment will start
as soon as the critical state requiring mechanical ventila-
tion is reached. Secondary outcomes include COVID-19
mortality, all-cause mortality, time (days) to improve in
clinical status from critical (WHO grade 6) to stable
(WHO grade 5), length of hospital stay for those who re-
cover, conversion rate of clinical status on day 7 after
treatment start, duration of ECMO, duration of vaso-
pressors, duration of oxygen therapy, SOFA score, main
blood cell counts (including lymphocyte subsets via
FACS), levels of CRP, LDH, D-dimer, ferritin, Il-6 and
other cytokines at days 4, 7 and 14 after start of treat-
ment, as well as delta CRP, LDH, D-dimer, ferritin, Il-6
and other cytokines at days 4, 7 and 14 compared to
baseline at start, PaO2/FiO2 ratio on days 1, 2, 3, 4, 7
and 14 after treatment start. Blood for analyses will al-
ways be drawn before EPO/placebo injection.
Fig. 2 Design of a double-blind, placebo-controlled, randomized proof-of-concept trial (phase IIb) on EPO treatment in severely affected COVID-
19 patients. Patients receive 40,000 IU recombinant human erythropoietin (EPO) or placebo plus standard care on the first day of mechanical
ventilation (day 1), as well as on days 2, 4, 7 and 14. Pulmonary function and laboratory work-up including inflammatory parameters are
monitored throughout in-hospital treatment, as well as on follow-up examinations at 3, 6 and 12 months after discharge. At discharge and after 3
and 12 months, magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain take place. BGA = blood gas analysis, FU = follow-up
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PCR, age > 18 years, all genders, respiratory failure (PaO2/
FiO2 < 300 or SatO2/FiO2 < 220) demanding mechanical
ventilation. Exclusion criteria are evidence of terminal
chronic end organ failure (renal, cardiac, hepatic, gastrointes-
tinal), thrombocytosis, life expectancy ≤24 h, and concomi-
tant potentially serious infections.
The intervention consists of intravenous application of
recombinant human EPO (40,000 IU) or placebo at start
of mechanical ventilation (day 1), repeated 24 h (day 2)
and 72 h (day 4) later, as well as on days 7 and 14 (cu-
mulative dose of 200,000 IU per patient). In addition, all
patients receive standard intensive care anticoagulation
(heparin), as anyhow strongly advisable for COVID-19
patient care (Levi et al. 2020; Paranjpe et al. 2020), and
can otherwise obtain any treatment considered necessary
for their clinical management.
Patients shall have follow-up examinations during
their hospital stay, daily while on mechanical ventilation,
and twice weekly thereafter (clinical and laboratory pa-
rameters) until discharge from hospital. Further clinical
follow-up shall be performed at 3, 6 and 12months after
discharge, including assessment of pulmonary function
and inflammation markers, neurological status, neuro-
psychological (cognitive) and psychopathological assess-
ment, if possible combined with MRI/MRS of the brain
at discharge as well as 3 and 12months thereafter.
Conclusion
In this brief review, we address COVID-19 and the need
of symptom-targeting therapeutic measures in thepresent pandemic situation where convincingly efficient
antiviral drugs and vaccination are still absent. We
present in brief chapters the major problems of severely
affected COVID-19 patients and delineate the potential
of EPO to relieve them. We conclude this article with a
clinical research design as basis of a planned clinical
trial, which is supposed to start shortly.
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